APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Endothelial Growth Factor B

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vascular Endothelial Growth Factor B Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchVascular Endothelial Growth Factor B Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Endothelial Growth Factor B Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Vascular Endothelial Growth Factor B Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Endothelial Growth Factor B Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Endothelial Growth Factor B Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Vascular Endothelial Growth Factor B market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vascular Endothelial Growth Factor B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vascular Endothelial Growth Factor B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vascular Endothelial Growth Factor B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vascular Endothelial Growth Factor B market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vascular Endothelial Growth Factor B market include Eli Lilly and Company, Regeneron Pharmaceuticals Inc, Formycon AG, CSL Ltd and Alteogen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vascular Endothelial Growth Factor B market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vascular Endothelial Growth Factor B and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vascular Endothelial Growth Factor B sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vascular Endothelial Growth Factor B market size, projected growth trends, production technologies, key applications, and end-use industries.

Vascular Endothelial Growth Factor B Segment by Company

Eli Lilly and Company

Regeneron Pharmaceuticals Inc

Formycon AG

CSL Ltd

Alteogen Inc

Vascular Endothelial Growth Factor B Segment by Type

CSL-346

Aflibercept

Aflibercept Biosimilar

Others

Vascular Endothelial Growth Factor B Segment by Application

Rectal Cancer

Diabetic Nephropathy

Retinal Vein Occlusion

Others

Vascular Endothelial Growth Factor B Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vascular Endothelial Growth Factor B status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vascular Endothelial Growth Factor B market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vascular Endothelial Growth Factor B significant trends, drivers, influence factors in global and regions.

6. To analyze Vascular Endothelial Growth Factor B competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Endothelial Growth Factor B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Endothelial Growth Factor B and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Endothelial Growth Factor B.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vascular Endothelial Growth Factor B market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vascular Endothelial Growth Factor B industry.

Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vascular Endothelial Growth Factor B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vascular Endothelial Growth Factor B in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vascular Endothelial Growth Factor B Industry Trends Table 2. Vascular Endothelial Growth Factor B Industry Drivers Table 3. Vascular Endothelial Growth Factor B Industry Opportunities and Challenges Table 4. Vascular Endothelial Growth Factor B Industry Restraints Table 5. Global Vascular Endothelial Growth Factor B Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vascular Endothelial Growth Factor B Revenue Share by Company (2021-2026) Table 7. Global Vascular Endothelial Growth Factor B Sales Volume by Company (k units) & (2021-2026) Table 8. Global Vascular Endothelial Growth Factor B Sales Volume Share by Company (2021-2026) Table 9. Global Vascular Endothelial Growth Factor B Average Price (US$/unit) of Company (2021-2026) Table 10. Global Vascular Endothelial Growth Factor B Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vascular Endothelial Growth Factor B Key Company Manufacturing Base & Headquarters Table 12. Global Vascular Endothelial Growth Factor B Company, Product Type & Application Table 13. Global Vascular Endothelial Growth Factor B Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vascular Endothelial Growth Factor B by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CSL-346 Table 18. Significant Companies of Aflibercept Table 19. Significant Companies of Aflibercept Biosimilar Table 20. Significant Companies of Others Table 21. Global Vascular Endothelial Growth Factor B Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Vascular Endothelial Growth Factor B Sales Volume by Type (2021-2026) & (k units) Table 23. Global Vascular Endothelial Growth Factor B Sales Volume by Type (2027-2032) & (k units) Table 24. Global Vascular Endothelial Growth Factor B Sales Volume Share by Type (2021-2026) Table 25. Global Vascular Endothelial Growth Factor B Sales Volume Share by Type (2027-2032) Table 26. Global Vascular Endothelial Growth Factor B Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vascular Endothelial Growth Factor B Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Vascular Endothelial Growth Factor B Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Vascular Endothelial Growth Factor B Sales Value Share by Type (2021-2026) Table 30. Global Vascular Endothelial Growth Factor B Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Rectal Cancer Table 32. Significant Companies of Diabetic Nephropathy Table 33. Significant Companies of Retinal Vein Occlusion Table 34. Significant Companies of Others Table 35. Global Vascular Endothelial Growth Factor B Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Vascular Endothelial Growth Factor B Sales Volume by Application (2021-2026) & (k units) Table 37. Global Vascular Endothelial Growth Factor B Sales Volume by Application (2027-2032) & (k units) Table 38. Global Vascular Endothelial Growth Factor B Sales Volume Share by Application (2021-2026) Table 39. Global Vascular Endothelial Growth Factor B Sales Volume Share by Application (2027-2032) Table 40. Global Vascular Endothelial Growth Factor B Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Vascular Endothelial Growth Factor B Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Vascular Endothelial Growth Factor B Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Vascular Endothelial Growth Factor B Sales Value Share by Application (2021-2026) Table 44. Global Vascular Endothelial Growth Factor B Sales Value Share by Application (2027-2032) Table 45. Global Vascular Endothelial Growth Factor B Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Vascular Endothelial Growth Factor B Sales by Region (2021-2026) & (k units) Table 47. Global Vascular Endothelial Growth Factor B Sales Market Share by Region (2021-2026) Table 48. Global Vascular Endothelial Growth Factor B Sales by Region (2027-2032) & (k units) Table 49. Global Vascular Endothelial Growth Factor B Sales Market Share by Region (2027-2032) Table 50. Global Vascular Endothelial Growth Factor B Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Vascular Endothelial Growth Factor B Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Vascular Endothelial Growth Factor B Sales Value Share by Region (2021-2026) Table 53. Global Vascular Endothelial Growth Factor B Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Vascular Endothelial Growth Factor B Sales Value Share by Region (2027-2032) Table 55. Global Vascular Endothelial Growth Factor B Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Vascular Endothelial Growth Factor B Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Vascular Endothelial Growth Factor B Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Vascular Endothelial Growth Factor B Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Vascular Endothelial Growth Factor B Sales by Country (2021-2026) & (k units) Table 60. Global Vascular Endothelial Growth Factor B Sales Market Share by Country (2021-2026) Table 61. Global Vascular Endothelial Growth Factor B Sales by Country (2027-2032) & (k units) Table 62. Global Vascular Endothelial Growth Factor B Sales Market Share by Country (2027-2032) Table 63. Global Vascular Endothelial Growth Factor B Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Vascular Endothelial Growth Factor B Sales Value Market Share by Country (2021-2026) Table 65. Global Vascular Endothelial Growth Factor B Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Vascular Endothelial Growth Factor B Sales Value Market Share by Country (2027-2032) Table 67. Eli Lilly and Company Company Information Table 68. Eli Lilly and Company Business Overview Table 69. Eli Lilly and Company Vascular Endothelial Growth Factor B Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Eli Lilly and Company Vascular Endothelial Growth Factor B Product Portfolio Table 71. Eli Lilly and Company Recent Development Table 72. Regeneron Pharmaceuticals Inc Company Information Table 73. Regeneron Pharmaceuticals Inc Business Overview Table 74. Regeneron Pharmaceuticals Inc Vascular Endothelial Growth Factor B Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Regeneron Pharmaceuticals Inc Vascular Endothelial Growth Factor B Product Portfolio Table 76. Regeneron Pharmaceuticals Inc Recent Development Table 77. Formycon AG Company Information Table 78. Formycon AG Business Overview Table 79. Formycon AG Vascular Endothelial Growth Factor B Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Formycon AG Vascular Endothelial Growth Factor B Product Portfolio Table 81. Formycon AG Recent Development Table 82. CSL Ltd Company Information Table 83. CSL Ltd Business Overview Table 84. CSL Ltd Vascular Endothelial Growth Factor B Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. CSL Ltd Vascular Endothelial Growth Factor B Product Portfolio Table 86. CSL Ltd Recent Development Table 87. Alteogen Inc Company Information Table 88. Alteogen Inc Business Overview Table 89. Alteogen Inc Vascular Endothelial Growth Factor B Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Alteogen Inc Vascular Endothelial Growth Factor B Product Portfolio Table 91. Alteogen Inc Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. Vascular Endothelial Growth Factor B Distributors List Table 95. Vascular Endothelial Growth Factor B Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Vascular Endothelial Growth Factor B Product Image Figure 2. Global Vascular Endothelial Growth Factor B Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vascular Endothelial Growth Factor B Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vascular Endothelial Growth Factor B Sales (2021-2032) & (k units) Figure 5. Global Vascular Endothelial Growth Factor B Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Vascular Endothelial Growth Factor B Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CSL-346 Image Figure 10. Aflibercept Image Figure 11. Aflibercept Biosimilar Image Figure 12. Others Image Figure 13. Global Vascular Endothelial Growth Factor B Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Vascular Endothelial Growth Factor B Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Vascular Endothelial Growth Factor B Sales Volume Share by Type (2021-2032) Figure 16. Global Vascular Endothelial Growth Factor B Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Vascular Endothelial Growth Factor B Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Vascular Endothelial Growth Factor B Sales Value Share by Type (2021-2032) Figure 19. Rectal Cancer Image Figure 20. Diabetic Nephropathy Image Figure 21. Retinal Vein Occlusion Image Figure 22. Others Image Figure 23. Global Vascular Endothelial Growth Factor B Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Vascular Endothelial Growth Factor B Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Vascular Endothelial Growth Factor B Sales Volume Share by Application (2021-2032) Figure 26. Global Vascular Endothelial Growth Factor B Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Vascular Endothelial Growth Factor B Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Vascular Endothelial Growth Factor B Sales Value Share by Application (2021-2032) Figure 29. Global Vascular Endothelial Growth Factor B Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Vascular Endothelial Growth Factor B Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Vascular Endothelial Growth Factor B Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Vascular Endothelial Growth Factor B Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Vascular Endothelial Growth Factor B Sales Value (2021-2032) & (US$ Million) Figure 34. North America Vascular Endothelial Growth Factor B Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Vascular Endothelial Growth Factor B Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Vascular Endothelial Growth Factor B Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Vascular Endothelial Growth Factor B Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Vascular Endothelial Growth Factor B Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Vascular Endothelial Growth Factor B Sales Value (2021-2032) & (US$ Million) Figure 40. South America Vascular Endothelial Growth Factor B Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Vascular Endothelial Growth Factor B Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Vascular Endothelial Growth Factor B Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Vascular Endothelial Growth Factor B Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Vascular Endothelial Growth Factor B Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • CSL-346
  • Aflibercept
  • Aflibercept Biosimilar
  • Others
Applications
  • Rectal Cancer
  • Diabetic Nephropathy
  • Retinal Vein Occlusion
  • Others
Companies covered
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc
  • Formycon AG
  • CSL Ltd
  • Alteogen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vascular Endothelial Growth Factor B Sales Value (2021-2032)
  4. 1.2.2 Global Vascular Endothelial Growth Factor B Sales Volume (2021-2032)
  5. 1.2.3 Global Vascular Endothelial Growth Factor B Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vascular Endothelial Growth Factor B Market Dynamics
  1. 2.1 Vascular Endothelial Growth Factor B Industry Trends
  2. 2.2 Vascular Endothelial Growth Factor B Industry Drivers
  3. 2.3 Vascular Endothelial Growth Factor B Industry Opportunities and Challenges
  4. 2.4 Vascular Endothelial Growth Factor B Industry Restraints
3 Vascular Endothelial Growth Factor B Market by Company
  1. 3.1 Global Vascular Endothelial Growth Factor B Company Revenue Ranking in 2025
  2. 3.2 Global Vascular Endothelial Growth Factor B Revenue by Company (2021-2026)
  3. 3.3 Global Vascular Endothelial Growth Factor B Sales Volume by Company (2021-2026)
  4. 3.4 Global Vascular Endothelial Growth Factor B Average Price by Company (2021-2026)
  5. 3.5 Global Vascular Endothelial Growth Factor B Company Ranking (2024-2026)
  6. 3.6 Global Vascular Endothelial Growth Factor B Company Manufacturing Base and Headquarters
  7. 3.7 Global Vascular Endothelial Growth Factor B Company Product Type and Application
  8. 3.8 Global Vascular Endothelial Growth Factor B Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vascular Endothelial Growth Factor B Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vascular Endothelial Growth Factor B Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vascular Endothelial Growth Factor B Market by Type
  1. 4.1 Vascular Endothelial Growth Factor B Type Introduction
  2. 4.1.1 CSL-346
  3. 4.1.2 Aflibercept
  4. 4.1.3 Aflibercept Biosimilar
  5. 4.1.4 Others
  6. 4.2 Global Vascular Endothelial Growth Factor B Sales Volume by Type
  7. 4.2.1 Global Vascular Endothelial Growth Factor B Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vascular Endothelial Growth Factor B Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Vascular Endothelial Growth Factor B Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Vascular Endothelial Growth Factor B Sales Value by Type
  11. 4.3.1 Global Vascular Endothelial Growth Factor B Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Vascular Endothelial Growth Factor B Sales Value by Type (2021-2032)
  13. 4.3.3 Global Vascular Endothelial Growth Factor B Sales Value Share by Type (2021-2032)
5 Vascular Endothelial Growth Factor B Market by Application
  1. 5.1 Vascular Endothelial Growth Factor B Application Introduction
  2. 5.1.1 Rectal Cancer
  3. 5.1.2 Diabetic Nephropathy
  4. 5.1.3 Retinal Vein Occlusion
  5. 5.1.4 Others
  6. 5.2 Global Vascular Endothelial Growth Factor B Sales Volume by Application
  7. 5.2.1 Global Vascular Endothelial Growth Factor B Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Vascular Endothelial Growth Factor B Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Vascular Endothelial Growth Factor B Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Vascular Endothelial Growth Factor B Sales Value by Application
  11. 5.3.1 Global Vascular Endothelial Growth Factor B Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Vascular Endothelial Growth Factor B Sales Value by Application (2021-2032)
  13. 5.3.3 Global Vascular Endothelial Growth Factor B Sales Value Share by Application (2021-2032)
6 Vascular Endothelial Growth Factor B Regional Sales and Value Analysis
  1. 6.1 Global Vascular Endothelial Growth Factor B Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vascular Endothelial Growth Factor B Sales by Region (2021-2032)
  3. 6.2.1 Global Vascular Endothelial Growth Factor B Sales by Region: 2021-2026
  4. 6.2.2 Global Vascular Endothelial Growth Factor B Sales by Region (2027-2032)
  5. 6.3 Global Vascular Endothelial Growth Factor B Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vascular Endothelial Growth Factor B Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vascular Endothelial Growth Factor B Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vascular Endothelial Growth Factor B Sales Value by Region (2027-2032)
  9. 6.5 Global Vascular Endothelial Growth Factor B Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vascular Endothelial Growth Factor B Sales Value (2021-2032)
  12. 6.6.2 North America Vascular Endothelial Growth Factor B Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vascular Endothelial Growth Factor B Sales Value (2021-2032)
  15. 6.7.2 Europe Vascular Endothelial Growth Factor B Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vascular Endothelial Growth Factor B Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vascular Endothelial Growth Factor B Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vascular Endothelial Growth Factor B Sales Value (2021-2032)
  21. 6.9.2 South America Vascular Endothelial Growth Factor B Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vascular Endothelial Growth Factor B Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vascular Endothelial Growth Factor B Sales Value Share by Country, 2025 VS 2032
7 Vascular Endothelial Growth Factor B Country-level Sales and Value Analysis
  1. 7.1 Global Vascular Endothelial Growth Factor B Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vascular Endothelial Growth Factor B Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vascular Endothelial Growth Factor B Sales by Country (2021-2032)
  4. 7.3.1 Global Vascular Endothelial Growth Factor B Sales by Country (2021-2026)
  5. 7.3.2 Global Vascular Endothelial Growth Factor B Sales by Country (2027-2032)
  6. 7.4 Global Vascular Endothelial Growth Factor B Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vascular Endothelial Growth Factor B Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vascular Endothelial Growth Factor B Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vascular Endothelial Growth Factor B Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vascular Endothelial Growth Factor B Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vascular Endothelial Growth Factor B Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Vascular Endothelial Growth Factor B Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Vascular Endothelial Growth Factor B Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 Regeneron Pharmaceuticals Inc
  8. 8.2.1 Regeneron Pharmaceuticals Inc Company Information
  9. 8.2.2 Regeneron Pharmaceuticals Inc Business Overview
  10. 8.2.3 Regeneron Pharmaceuticals Inc Vascular Endothelial Growth Factor B Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Regeneron Pharmaceuticals Inc Vascular Endothelial Growth Factor B Product Portfolio
  12. 8.2.5 Regeneron Pharmaceuticals Inc Recent Developments
  13. 8.3 Formycon AG
  14. 8.3.1 Formycon AG Company Information
  15. 8.3.2 Formycon AG Business Overview
  16. 8.3.3 Formycon AG Vascular Endothelial Growth Factor B Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Formycon AG Vascular Endothelial Growth Factor B Product Portfolio
  18. 8.3.5 Formycon AG Recent Developments
  19. 8.4 CSL Ltd
  20. 8.4.1 CSL Ltd Company Information
  21. 8.4.2 CSL Ltd Business Overview
  22. 8.4.3 CSL Ltd Vascular Endothelial Growth Factor B Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSL Ltd Vascular Endothelial Growth Factor B Product Portfolio
  24. 8.4.5 CSL Ltd Recent Developments
  25. 8.5 Alteogen Inc
  26. 8.5.1 Alteogen Inc Company Information
  27. 8.5.2 Alteogen Inc Business Overview
  28. 8.5.3 Alteogen Inc Vascular Endothelial Growth Factor B Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Alteogen Inc Vascular Endothelial Growth Factor B Product Portfolio
  30. 8.5.5 Alteogen Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vascular Endothelial Growth Factor B Value Chain Analysis
  2. 9.1.1 Vascular Endothelial Growth Factor B Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vascular Endothelial Growth Factor B Sales Mode & Process
  6. 9.2 Vascular Endothelial Growth Factor B Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vascular Endothelial Growth Factor B Distributors
  9. 9.2.3 Vascular Endothelial Growth Factor B Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst